Risk was comparable in women on aromatase
inhibitors (AIs) only and in those who used sequential tamoxifen followed by an AI, Reina Haque, Ph.D., reported at the San Antonio Breast Cancer Symposium.
It has been hypothesized that male and female sex differentiation is determined by aromatase
activity in fish as Cyp19 gene is highly conserved in fish .
Therefore, hormone-receptor-positive breast cancer can be treated by either blocking the ER with agents such as the selective ER modulator tamoxifen, or by reducing the production of oestrogens with aromatase
inhibitors (AIs) .
is the name of the enzyme present in female and male bodies that transforms testosterone into estrogen in one step.
These mutations activate the estrogen receptor when there is no estrogen--as is the case when a patient takes an aromatase
inhibitor," says lead study author Dan Robinson, PhD.
is responsible for the final step in estrogen biosynthesis, catalyzing the aromatization of androstenedione and testosterone into estrone and estradiol, respectively (Haynes et al., 2003), and its activity determines the androgen-to-estrogen ratio in developing gonads (Navarro-Martin et al., 2009).
Conclusions: Everolimus combined with an aromatase
inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase
Young that, for patients who have endometriosis and pelvic pain and who do not experience sufficient relief with an OC or GnRH agonist, a combination of an OC and an aromatase
inhibitor, or NEA plus an aromatase
inhibitor, may be effective.
inhibitors, CA Ovary, Granulosa cell tumour, Anastrozole, Oncology Royal Hospital.
Such reductions were subsequently confirmed in trials testing the other two potent aromatase
inhibitors, letrozole and exemestane.
Sonia Servaja of Hospital del Mar in Barcelona, and colleagues, assessed the association between 25-hydroxy-vitamin D (25[OH]D) concentrations and bone loss at baseline, after 3 months of supplementation, and after 1 year, in patients receiving aromatase
inhibitor therapy for early-stage breast cancer.
Not all breast cancer patients are eligible to take tamoxifen or aromatase
inhibitors, but for some patients with estrogen-sensitive tumors, doctors are now prescribing both drugs, a five-year course of tamoxifen followed by a five-year course of an aromatase